Preparation and characterization of monoclonal antibody against glypican-3

Hybridoma

Volumn 31, Issue 6, 2012, Pages 455-461

  Ma, Rui Juan ^a   Wang, Sui Hai ^a   Qin, Shi Ni ^a   Wang, Xiao Bo ^a   Li, Gao Fei ^a   Li, Ming ^a   Xu, Wei Wen ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLYPICAN 3; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HYBRIDOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GLYPICANS; HUMANS; HYBRIDOMAS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; TUMOR MARKERS, BIOLOGICAL;

MUS;

EID: 84871276889     PISSN: 15540014     EISSN: 15578348     Source Type: Journal    
DOI: 10.1089/hyb.2012.0030     Document Type: Article

References (32)

1. Schafer DF, and Sorrell MF: Hepatocellular carcinoma. Lancet 1999;353:1253-1257.
2. Okuda K: Hepatocellular carcinoma. J Hepatol 2000;32:225-237.
3. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, and Terracciano LM: Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4387 tissue samples. Am J Clin Pathol 2008;129:899-906.
4. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yama-moto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T, and Aburatani H: Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-2423.
5. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, and Filmus J: Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastro-enterology 2003;125(1):89-97.
6. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, and Nishimura Y: Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306(1):16-25.
7. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T, and Nishimura Y: Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004;10:6612-6621.
8. Filmus J, and Selleck SB: Glypicans: proteoglycans with a surprise. J Clin Invest 2001;108:497-501.
9. Filmus J: The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans. Glycoconj J 2002;19:319-323.
10. De Cat B, Muyldermans SY, Coomans C, Degeest G, Vanderschueren B, Creemers J, Biemar F, Peers B, and David G: Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling and gastrulation movements. J Cell Biol 2003;163:625-635.
11. Capurro MI, Shi W, Sandal S, and Filmus J: Processing by convertases is not required for glypican-3-induced stimulation of hepatocellular carcinoma growth. J Biol Chem 2005;280:41201-41206.
12. Capurro MI, Xiang YY, Lobe C and Filmus J: Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005;65:6245-6254.
13. Filmus J, Capurro M, and Rast J: Glypicans. Genome Biol 2008;9:224.
14. Torisu Y, Watanabe A, Nonaka A, Midorikawa Y, Makuuchi M, Shimamura T, Sugimura H, Niida A, Akiyama T, Iwanari H, Kodama T, Zeniya M, and Aburatani H: Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci 2008;99:1139-1146.
15. Oliver F, Christians JK, Liu X, Rhind S, Verma V, Davison C, Brown SD, Denny P, and Keightley PD: Regulatory variation at glypican-3 underlies a major growth QTL in mice. PLoS Biol 2005;3:135.
16. Ligato S, Mandich D, and Cartun RW: Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immu-nocytochemical study. Mod Pathol 2008;21:626-631.
17. Shafizadeh N, Ferrell LD, and Kakar S: Utility and limitations of glypican-3 expression for the diagnosis of hepato-cellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008;21:1011-1018.
18. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Mid-orikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, and Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-1598.
19. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, and Roskams T: Glypi-can-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasialike nodules. Am J Surg Pathol 2006;30:1405-1411.
20. Sugimura J, Foster RS, Cummings OW, Kort EJ, Takahashi M, Lavery TT, Furge KA, Einhorn LH, and Teh BT: Gene expression profiling of early-and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res 2004;10:2368-2378.
21. Iczkowski KA, and Butler SL: New immunohistochemical markers in testicular tumors. Anal Quant Cytol Histol 2006;28:181-187.
22. Hsu HC, Cheng W, and Lai PL: Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellu-lar carcinoma: biological significance and temporospatial distribution. Cancer Res 1997;57(22):5179-5184.
23. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, and Roskams T: Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006; 30:1405-1411.
24. Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M, and Abur-atani H: Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103(4):455-465.
25. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, Montorsi M, Torzilli G, Tommasini M, Terrac-ciano L, Tornillo L, Vecchione R, and Roncalli M: Diagnostic value of HSP70, glypican 3, and glutamine synthetase in he-patocellular nodules in cirrhosis. Hepatology 2007;45:725-734.
26. Llovet JM, Chen Y, Wurmbach E, Roayaie S, Fiel MI, Schwartz M, Thung SN, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, and Friedman SL: A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131:1758-1767.
27. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Ko-bayashi N, Kinoshita T, and Nakatsura T: Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009;34:649-656.
28. Ding GH, Wang HY, Chen H, Wu MC, Man XB, Cong WM, Yang JH, Cheng SQ, Li N, and Shen L: Expression of the glypican-3 gene in alpha-fetoprotein-negative human hepa-tocellular carcinoma. Chin-Germ J Clin Oncol 2005;4:262-266.
29. Filmus J, and Capurro M: Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 2004;8:207-212.
30. Ho M, and Kim H: Glypican-3: a new target for cancer im-munotherapy. Eur J Cancer 2011;47(3): 333-338.
31. Catanzariti AM, Soboleva TA, Jans DA, Board PG, and Baker RT: An efficient system for high-level expression and easy purification of authentic recombinant proteins [J]. Protein Sci 2004;13(5):1331-1339.
32. GE Healthcare. The Recombinant Protein Purification Handbook, Principles and Methods, 2012. www.gelifesciences.com/gehcls-images/GELS/Related%20Content/ Files/1336168762999/litdoc18114275-20120505001440.pdf